medipace limited
medipace limited Company Information
Company Number
10943570
Website
medipace.comRegistered Address
167-169 great portland street, 5th floor, london, W1W 5PF
Industry
Research and experimental development on biotechnology
Telephone
441628272120
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
guy beatty yeoman 40%
sandeep kumar bagga 40%
View Allmedipace limited Estimated Valuation
Pomanda estimates the enterprise value of MEDIPACE LIMITED at £282.3k based on a Turnover of £283.1k and 1x industry multiple (adjusted for size and gross margin).
medipace limited Estimated Valuation
Pomanda estimates the enterprise value of MEDIPACE LIMITED at £0 based on an EBITDA of £-29.9k and a 4x industry multiple (adjusted for size and gross margin).
medipace limited Estimated Valuation
Pomanda estimates the enterprise value of MEDIPACE LIMITED at £236.7k based on Net Assets of £103.5k and 2.29x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Medipace Limited Overview
Medipace Limited is a live company located in london, W1W 5PF with a Companies House number of 10943570. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in September 2017, it's largest shareholder is guy beatty yeoman with a 40% stake. Medipace Limited is a young, micro sized company, Pomanda has estimated its turnover at £283.1k with low growth in recent years.
Upgrade for unlimited company reports & a free credit check
Medipace Limited Health Check
Pomanda's financial health check has awarded Medipace Limited a 1.5 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 7 areas for improvement. Company Health Check FAQs
1 Strong
2 Regular
7 Weak
Size
annual sales of £283.1k, make it smaller than the average company (£3m)
- Medipace Limited
£3m - Industry AVG
Growth
3 year (CAGR) sales growth of 2%, show it is growing at a slower rate (13.1%)
- Medipace Limited
13.1% - Industry AVG
Production
with a gross margin of 27.6%, this company has a higher cost of product (53.9%)
- Medipace Limited
53.9% - Industry AVG
Profitability
an operating margin of -10.6% make it less profitable than the average company (0%)
- Medipace Limited
0% - Industry AVG
Employees
with 4 employees, this is below the industry average (40)
4 - Medipace Limited
40 - Industry AVG
Pay Structure
on an average salary of £71.2k, the company has an equivalent pay structure (£71.2k)
- Medipace Limited
£71.2k - Industry AVG
Efficiency
resulting in sales per employee of £70.8k, this is less efficient (£127.6k)
- Medipace Limited
£127.6k - Industry AVG
Debtor Days
it gets paid by customers after 173 days, this is later than average (51 days)
- Medipace Limited
51 days - Industry AVG
Creditor Days
its suppliers are paid after 59 days, this is close to average (62 days)
- Medipace Limited
62 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Medipace Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Medipace Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 24.3%, this is a lower level of debt than the average (50%)
24.3% - Medipace Limited
50% - Industry AVG
MEDIPACE LIMITED financials
Medipace Limited's latest turnover from March 2023 is estimated at £283.1 thousand and the company has net assets of £103.5 thousand. According to their latest financial statements, Medipace Limited has 4 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2023 | Mar 2022 | Mar 2021 | Oct 2020 | Jan 2020 | Sep 2018 | |
|---|---|---|---|---|---|---|
| Turnover | ||||||
| Other Income Or Grants | ||||||
| Cost Of Sales | ||||||
| Gross Profit | ||||||
| Admin Expenses | ||||||
| Operating Profit | ||||||
| Interest Payable | ||||||
| Interest Receivable | ||||||
| Pre-Tax Profit | ||||||
| Tax | ||||||
| Profit After Tax | ||||||
| Dividends Paid | ||||||
| Retained Profit | ||||||
| Employee Costs | ||||||
| Number Of Employees | 4 | 4 | 4 | 3 | 2 | 2 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2023 | Mar 2022 | Mar 2021 | Oct 2020 | Jan 2020 | Sep 2018 | |
|---|---|---|---|---|---|---|
| Tangible Assets | 2,260 | 1,902 | 2,297 | 1,671 | 213 | 697 |
| Intangible Assets | 0 | 0 | 818 | 863 | 606 | 437 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 2,260 | 1,902 | 3,115 | 2,534 | 819 | 1,134 |
| Stock & work in progress | 0 | 0 | 48,956 | 0 | 21,774 | 0 |
| Trade Debtors | 134,492 | 272,075 | 46,905 | 102,634 | 54,021 | 36,800 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 0 | 0 | 2,385 | 3,262 | 0 | 719 |
| Cash | 0 | 0 | 53,036 | 96,272 | 102,548 | 20,173 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 134,492 | 272,075 | 151,282 | 202,168 | 178,343 | 57,692 |
| total assets | 136,752 | 273,977 | 154,397 | 204,702 | 179,162 | 58,826 |
| Bank overdraft | 0 | 0 | 0 | 541 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 33,208 | 140,494 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 0 | 0 | 154,393 | 204,158 | 173,971 | 58,669 |
| total current liabilities | 33,208 | 140,494 | 154,393 | 204,699 | 173,971 | 58,669 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 33,208 | 140,494 | 154,393 | 204,699 | 173,971 | 58,669 |
| net assets | 103,544 | 133,483 | 4 | 3 | 5,191 | 157 |
| total shareholders funds | 103,544 | 133,483 | 4 | 3 | 5,191 | 157 |
| Mar 2023 | Mar 2022 | Mar 2021 | Oct 2020 | Jan 2020 | Sep 2018 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Operating Profit | ||||||
| Depreciation | 1,103 | 456 | 768 | 484 | 388 | |
| Amortisation | 110 | 45 | 83 | 101 | 53 | |
| Tax | ||||||
| Stock | 0 | -48,956 | 48,956 | 0 | 21,774 | 0 |
| Debtors | -137,583 | 222,785 | -56,606 | 105,896 | 54,021 | 37,519 |
| Creditors | -107,286 | 140,494 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | -154,393 | -49,765 | 204,158 | 173,971 | 58,669 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||||
| Investing Activities | ||||||
| capital expenditure | ||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||
| Financing Activities | ||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||
| interest | ||||||
| cash flow from financing | ||||||
| cash and cash equivalents | ||||||
| cash | 0 | -53,036 | -43,236 | 96,272 | 102,548 | 20,173 |
| overdraft | 0 | 0 | -541 | 541 | 0 | 0 |
| change in cash | 0 | -53,036 | -42,695 | 95,731 | 102,548 | 20,173 |
medipace limited Credit Report and Business Information
Medipace Limited Competitor Analysis
Perform a competitor analysis for medipace limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in W1W area or any other competitors across 12 key performance metrics.
medipace limited Ownership
MEDIPACE LIMITED group structure
Medipace Limited has no subsidiary companies.
Ultimate parent company
MEDIPACE LIMITED
10943570
medipace limited directors
Medipace Limited currently has 3 directors. The longest serving directors include Dr Guy Yeoman (Sep 2017) and Dr Sandeep Bagga (Jan 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Guy Yeoman | England | 58 years | Sep 2017 | - | Director |
| Dr Sandeep Bagga | England | 45 years | Jan 2020 | - | Director |
| Dr Jennifer Royle | England | 47 years | Apr 2021 | - | Director |
P&L
March 2023turnover
283.1k
-43%
operating profit
-29.9k
0%
gross margin
27.6%
-6.72%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
103.5k
-0.22%
total assets
136.8k
-0.5%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
medipace limited company details
company number
10943570
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
September 2017
age
7
incorporated
UK
accounts
Micro-Entity Accounts
ultimate parent company
previous names
N/A
last accounts submitted
March 2023
address
167-169 great portland street, 5th floor, london, W1W 5PF
accountant
DAFFERNS LLP
auditor
-
medipace limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to medipace limited.
medipace limited Companies House Filings - See Documents
| date | description | view/download |
|---|
